TherapeuticsMD, Inc.
About TherapeuticsMD, Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $1.8M
- Net income
- -$569.0K
- Total assets
- $37.7M
- Market cap
- $23.0M
- Operating margin
- -145.3%
- Net margin
- -18.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.0M
- Operating expenses
- $7.4M
- Operating income
- -$4.4M
- Net income
- -$569.0K
- EPS (basic)
- $-0.05
- EPS (diluted)
- $-0.05
Balance sheet
- Total assets
- $37.7M
- Current assets
- $14.4M
- Total liabilities
- $10.8M
- Current liabilities
- $4.8M
- Shareholders’ equity
- $26.9M
Cash flow
- Operating cash flow
- $2.4M
- Net cash flow
- $2.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $23.0M
- EPS (diluted)
- $-0.05
- Shares outstanding
- 12.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 28, 2002
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $569.0K in FY2024.
- Revenue declined 97% from FY2021 to FY2025.
- Trading 32% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TherapeuticsMD, Inc..
Write a review
News about TherapeuticsMD, Inc.
News & sentiment via Polygon.io
